The Age of Personalized Medicine: Trends and Opportunities Reflected in the U.S. Experience
17 April 2013
Foley and ChinaBio invite you to join us for our upcoming executive workshop, which will explore this paradigm shift toward personalized medicine and its global implications for China’s life sciences business executives, health care professionals, and academic researchers.
Topics to be discussed include:
- Business and social factors driving the move to personalized medicine, including non-sustainable medical costs, a decline in pharma R&D productivity, and the rise of patient-oriented health care
- Regulatory and intellectual property challenges to formulating a viable business model in the personalized medicine arena
- Potential for strategic collaborations with U.S. companies focused on different aspects of personalized medicine, such as genomic sequencing, biomarker substantiation, genetic testing, and electronic health records
- Post-grant patent issues, reducing patent litigation cost, and other risk management issues in the United States
Confirmed Speakers
- Andrew S. Baluch, Special Counsel, Intellectual Property Department and China Practice, Foley & Lardner LLP
- Nathan A. Beaver, Partner, Life Sciences Industry Team, Foley & Lardner LLP
- Song (Max) Lin, China Associate, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP
- Alex Y. Nie, Associate, Chemical, Biotechnology & Pharmaceutical Practice and Life Sciences Industry Team, Foley & Lardner LLP
- Greg B. Scott, President and Founder, ChinaBio LLC
This workshop is complimentary; however, due to seating limitations, pre-registration is required. An acknowledgement email will be sent upon receipt of your registration request.
For more information, contact Delia Dai at [email protected] or 001.312.832.4506, or Emily Zhang at [email protected] or 86.21.5137.0751, ext. 20.
People
Related Insights
18 April 2025
Foley Viewpoints
Supreme Court Ends Circuit Split with Ruling That Plaintiffs Can Seek RICO Damages for Certain Personal Injury Claims
The U.S. Supreme Court has broadened plaintiffs’ ability to sue under the Racketeer Influenced and Corrupt Organizations Act (RICO) for economic loss stemming from personal injury.
30 April 2025
Events
Tariff Blitz Webinar
Join us for a wide-ranging discussion of the Trump administration tariffs and how to risk plan for them.
17 April 2025
Tariff & International Trade Resource
The Non-Compliant Cat in the Hat
So, just before Easter, in 1957, a little book you may have heard of, called The Cat in the Hat, made its first appearance. Theodore Geisel — writing under the name “Dr. Suess” — later said that of all his children’s books, he was proudest of this one, because “it had something to do with the death of the Dick and Jane primers,” which he thought would bore any child to tears.